Results: DCTA

Search articles by EPIC code

NEWSFLOW

Directa Plus (#DCTA) – revenue “acceleration”, but what about the bottom-line?

2022-06-17 07:27:23

views

Directa Plus – 2021 results, how “comfortable” with forecasts?...

Producer and supplier of graphene nanoplatelets-based products Directa Plus (DCTA) has announced 2021 results emphasising “revenue and profitability which have exceeded consensus market expectations” and “a number of exciting opportunities in our targeted markets”. So what of a current 121.5p share price?...

By Steve Moore
2022-05-05 14:54:57

NEWSFLOW

Directa Plus (#DCTA) – “partnership to develop automotive fabrics”, but RNS Reach ramptastic

2022-04-22 07:55:31

views

Directa Plus – emphasised ‘vital step’ helps share price rise, but is it justified?...

Shares in company which describes itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) are currently further higher today to 123p on the back of a “US EPA Authorises Grafysorber for Use in US”-titled announcement. What does this latest here mean?...

By Steve Moore
2022-04-04 15:39:28

views

Directa Plus – ‘news’ helps share price rise, but is it justified?...

Having commenced November at a 136p share price, two subsequent announcements have helped shares in Directa Plus (DCTA) up to a current 160p. So what’s this latest news from this ‘graphene nanoplatelets-based products’ company?...

By Steve Moore
2021-11-11 16:28:58

views

Directa Plus – ‘additional funds to accelerate strategic programme’, but what’s already in the price?...

Previously writing on graphene nanoplatelets-based products company Directa Plus (DCTA), in June I concluded with the shares at 121.5p, having expressed cash burn concern, I continued to avoid. Today an “Additional Italian Government Covid Recovery Loan” announcement.

By Steve Moore
2021-10-14 11:32:55

views

Directa Plus – “pleased… trading in line with market expectations”. What are those expectations though?...

Self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) “is pleased to report that this strong revenue growth is continuing in the last two months of the current first half”. What does it mean financially?...

By Steve Moore
2021-06-23 11:42:30

views

Directa Plus – 2020 results, what does ‘rapid growth potential’ mean financially?

Having exceeded 140p in February, shares in self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) last closed at 112.5p and are currently further lower on the back of 2020 results announcement. So what’s the detail?...

By Steve Moore
2021-05-17 14:15:49

views

Directa Plus – patent grant, a step towards addressing a large global market?

Self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”, Directa Plus (DCTA) has announced it “has been granted an EU-wide patent covering the use of its G+® graphene in golf ball applications”. It emphasises this “the first step towards addressing a very large global market” and the shares have responded currently 4% higher to 106p, a £65 million market capitalisation. Is this justified?...

By Steve Moore
2021-03-29 15:15:29

views

Directa Plus – trading update argues “a strong pipeline of opportunities”. It looks to need them...

Self-styled “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) has made a trading update including noting 2020 revenue “further improvement” from previously reported expectations, Q1 2021 revenue expected to be up 20% from the same period last year and that “there is a strong pipeline of opportunities”. Why are the shares though still well down from 145p reached earlier this year?...